Table 3. Influence of AD co-pathology and mutation status on cerebrospinal fluid phosphorylated tau levels in FTLD.

Table displays optimal multivariate model using natural-log transformed cerebrospinal fluid phosphorylated-tau measurement as the dependent variable to test A) the independent association of the categorical presence of Alzheimer’s disease co-pathology (i.e. AD Braak tau co-pathology stage=B2/B3 vs B0/B1) in the total FTLD cohort (Model R²=0.14, F(4,71)=2.8, p<0.05) and B) the independent association of the presence of a pathogenic mutation with CSF p-tau measurement in the subset of patients with “pure” (AD Braak tau co-pathology stage=B0/B1) FTLD (Model R²=0.20, F(4,58)=3.5, p<0.02).

A) TOTAL FTLD COHORT
VARIABLE	Beta (95% CI)	T-VALUE	P-VALUE
AD co-pathology (Braak B2/B3 vs B0/B1)	0.4 (0.04 – 0.7)	2.3	0.027
FTLD Pathology Group (FTLD-Tau vs FTLD-TDP)	0.2 (−0.06 – 0.5)	01.54	0.127
Age at CSF Collection (years)	0.01 (−0.002 – 0.02)	1.7	0.086
CSF Collection- Death Interval (years)	0.01 (−0.03 – 0.06)	0.6	0.545
Intercept	1.5 (0.6 – 2.3)	3.6	0.001
B) “PURE” FTLD COHORT
VARIABLE	Beta (95% CI)	T-VALUE	P-VALUE
Mutation Status	0.3 (0.004 – 0.5)	2.0	0.047
FTLD Pathology Group (FTLD-Tau vs FTLD-TDP)	0.3 (0.1 – 0.6)	2.9	0.005
Age at CSF Collection (years)	0.01 (0 – 0.02)	1.9	0.052
CSF Collection- Death Interval (years)	0.003 (−0.03 – 0.04)	0.2	0.865
Intercept	1.4 (0.6 – 2.1)	3.5	0.001